Simposio Internacional: Enfermedades neuromusculares: es el tiempo para el tratamiento
***International Symposium**: Neuromuscular diseases: It's time for treatment*
Madrid, 15 y 16 de noviembre de 2012
Madrid, November 15-16, 2012

New antibodies related to neuromuscular diseases

Isabel Illa Sendra

Neuromuscular diseases are an heterogeneous group of disease of different origin. They may be due to neurodegenerative, genetic, metabolic or other causes and some are immune-mediated. Chronic inflammatory demyelinating neuropathy (CIDP), multifocal motor neuropathy (MMN), inflammatory myopathies (IM) or Myasthenia Gravis (MG)) are among the neuromuscular diseases of probable autoimmune origin because they respond to plasmapheresis or immunosupressive drugs and because antibodies to relevant antigens or inflammation have been found in a number of patients in these groups of pathologies.
I will review the importance of unraveling biomarkers for these diseases in order to better understand the clinical features, to further study their immunopathogenesis, and to apply more specific treatments. Specifically I will discuss the clinical findings , long-tern immunological evolution and response to therapy of patients with MG-MuSK+ versus patients MG-AchR+. I will also present the clinical phenotype of patients with CIDP and antibodies to the CNTN-1- or the CNTN-1-CAPR-1 complex, proteins present at the paranodes of Ranvier.